Climb Bio, Inc. (CLYM)
NGM – Real vaqt narxi. Valyuta: USD
7.02
-0.09 (-1.27%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
7.02
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:10 PM EDT

NGM – Real vaqt narxi. Valyuta: USD
7.02
-0.09 (-1.27%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
7.02
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:10 PM EDT
Climb Bio, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, immun vositali kasalliklari bilan yashovchi bemorlar uchun qondirilmagan ehtiyojlarni qondirish uchun terapiyalarni ishlab chiqishga qaratilgan. Kompaniyaning asosiy mahsulot nomzodi budoprutug bo'lib, u B-hujayralari vositali kasalliklarni davolash uchun mo'ljallangan anti-CD19 monoklonal antidir. Kompaniya, shuningdek, birlamchi membranli nefropatiya va immun trombotsitopeniyani davolash uchun 2-bosqichli klinik sinovlarda bo'lgan budoprutugni ishlab chiqmoqda; va tizimli qizil yug'urish uchun ko'rsatilgan 1b-bosqichli klinik sinov. Bundan tashqari, kompaniya immunoglobin A nefropatiyasi (IgAN) va boshqa B-hujayralari vositali kasalliklarni davolash uchun proloferatsiyaga undovchi ligand (APRIL) ga qarshi preclinical bosqichdagi monoklonal antini ishlab chiqmoqda. Kompaniya ilgari Eliem Therapeutics, Inc. nomi bilan tanilgan va 2024 yil oktyabr oyida Climb Bio, Inc. deb o'zgartirilgan. Climb Bio, Inc. 2018 yilda tashkil etilgan va Vellesli-Xils, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | CEO, President & Director |
| Dr. Edgar D. Charles M.D., M.Sc. | Chief Medical Officer |
| Dr. Perrin Wilson B.S., Ph.D. | Chief Business Officer |
| Dr. Susan Altschuller M.B.A., Ph.D. | Chief Financial Officer |
| Mr. Adam Villa | Senior VP of Technical Operations |
| Ms. Ashley Jones | Senior VP of People & Workforce Strategy |
| Ms. Chandra Adams J.D. | VP & General Counsel |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-05 | S-8 | d124511ds8.htm |
| 2026-01-08 | 8-K | d92848d8k.htm |
| 2025-12-31 | 8-K | d19559d8k.htm |
| 2025-12-11 | 8-K | d48098d8k.htm |
| 2025-11-06 | 10-Q | clym-20250930.htm |
| 2025-10-17 | 8-K | d34212d8k.htm |
| 2025-10-01 | 8-K | d33819d8k.htm |
| 2025-09-29 | 8-K | d942245d8k.htm |
| 2025-08-12 | 10-Q | clym-20250630.htm |
| 2025-06-18 | 8-K | d939351d8k.htm |
| Ms. Cindy J. Driscoll M.B.A. |
| Senior Vice President of Finance |
| Ms. Janaki M. Subramanyam M.Sc. | VP & Head of Regulatory Affairs |